CR20200218A - Mitoflavoscinas: la fijaciòn como objetivo de enzimas que contienen flavina elimina cèlulas madre cancerosas (cscs) al inhibir la respiraciòn mitocondrial - Google Patents

Mitoflavoscinas: la fijaciòn como objetivo de enzimas que contienen flavina elimina cèlulas madre cancerosas (cscs) al inhibir la respiraciòn mitocondrial

Info

Publication number
CR20200218A
CR20200218A CR20200218A CR20200218A CR20200218A CR 20200218 A CR20200218 A CR 20200218A CR 20200218 A CR20200218 A CR 20200218A CR 20200218 A CR20200218 A CR 20200218A CR 20200218 A CR20200218 A CR 20200218A
Authority
CR
Costa Rica
Prior art keywords
mitoflavoscins
flavin
cscs
targeting
stem cells
Prior art date
Application number
CR20200218A
Other languages
English (en)
Inventor
Michael P Lisanti
Federica Sotgia
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of CR20200218A publication Critical patent/CR20200218A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
    • C07C25/18—Polycyclic aromatic halogenated hydrocarbons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D347/00—Heterocyclic compounds containing rings having halogen atoms as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/12—Heterocyclic compounds containing pteridine ring systems containing pteridine ring systems condensed with carbocyclic rings or ring systems
    • C07D475/14—Benz [g] pteridines, e.g. riboflavin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a compuestos que se enlazan a enzimas que contienen flavina e inhiben la función mitocondrial, referidos en este documento como mitoflavoscinas. Se describen métodos para examinar compuestos por la inhibición mitocondrial y propiedades anticancerosas. También se describen métodos para usar mitoflavoscinas para prevenir o tratar el cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar mitoflavoscinas para proporcionar beneficios anti-envejecimiento. También se dan a conocer compuestos específicos de mitoflavoscina.
CR20200218A 2017-10-24 2018-10-23 Mitoflavoscinas: la fijaciòn como objetivo de enzimas que contienen flavina elimina cèlulas madre cancerosas (cscs) al inhibir la respiraciòn mitocondrial CR20200218A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762576287P 2017-10-24 2017-10-24
PCT/US2018/057093 WO2019083997A1 (en) 2017-10-24 2018-10-23 MITOFLAVOSCINS: TARGETING FLAVIN-CONTAINING ENZYMES THAT REMOVE CANCER STEM CELLS (CSC) BY INHIBITING MITOCHONDRIAL BREATHING

Publications (1)

Publication Number Publication Date
CR20200218A true CR20200218A (es) 2020-12-23

Family

ID=66247987

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200218A CR20200218A (es) 2017-10-24 2018-10-23 Mitoflavoscinas: la fijaciòn como objetivo de enzimas que contienen flavina elimina cèlulas madre cancerosas (cscs) al inhibir la respiraciòn mitocondrial

Country Status (20)

Country Link
US (1) US11497749B2 (es)
EP (1) EP3700512A4 (es)
JP (1) JP2021500374A (es)
KR (1) KR20200069365A (es)
CN (1) CN111565715A (es)
AU (1) AU2018354143A1 (es)
BR (1) BR112020008022A2 (es)
CA (1) CA3079952A1 (es)
CL (1) CL2020001108A1 (es)
CR (1) CR20200218A (es)
CU (1) CU20200039A7 (es)
EC (1) ECSP20027220A (es)
IL (1) IL274116A (es)
MX (1) MX2020004211A (es)
PE (1) PE20210166A1 (es)
PH (1) PH12020550476A1 (es)
RU (1) RU2020116649A (es)
SG (1) SG11202003675PA (es)
WO (1) WO2019083997A1 (es)
ZA (1) ZA202002663B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102017220539A1 (de) 2017-11-17 2019-05-23 Zf Friedrichshafen Ag Verfahren zum Betreiben eines Systems aus einem landwirtschaftlichen Arbeitsfahrzeug und zumindest einem an diesem angeordneten Arbeitsgerät
US11497759B2 (en) * 2017-12-01 2022-11-15 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
PE20211006A1 (es) 2018-10-02 2021-06-01 Lunella Biotech Inc Derivados de azitromicina y roxitromicina como farmacos senoliticos
EP3976197A4 (en) 2019-05-24 2023-07-19 Lunella Biotech, Inc. THERAPEUTIC AGENTS AND METHODS FOR PREDICTING AND OVERCOMING ENDOCRINE RESISTANCE IN BREAST CANCER

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9321558D0 (en) * 1993-10-19 1993-12-08 Radopath Ltd Anti-viral agents
JPH09309874A (ja) 1996-05-21 1997-12-02 Fuji Photo Film Co Ltd ポジ型感光性組成物
US6498181B1 (en) 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
WO2001006756A2 (en) 1999-07-16 2001-01-25 Maxim Pharmaceuticals, Inc. Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes
JP2002221787A (ja) 2001-01-25 2002-08-09 Fuji Photo Film Co Ltd ポジ型感放射線性組成物
JP4098483B2 (ja) 2001-03-12 2008-06-11 富士フイルム株式会社 平版印刷版原版
JP2003207898A (ja) * 2001-11-08 2003-07-25 Fuji Photo Film Co Ltd ポジ型レジスト組成物
JP4648319B2 (ja) * 2003-08-22 2011-03-09 アンティポディーン ファーマシューティカルズ インコーポレイティド ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体
JP2005091713A (ja) * 2003-09-17 2005-04-07 Fuji Photo Film Co Ltd ポジ型レジスト組成物及びそれを用いたパターン形成方法。
GB0329716D0 (en) 2003-12-23 2004-01-28 Amersham Plc Radical trap
WO2005099721A2 (en) * 2004-04-15 2005-10-27 The Regents Of The University Of California Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung
JP2009057330A (ja) * 2007-08-31 2009-03-19 Aspion Kk ジフェニレンヨードニウム化合物
WO2009038656A1 (en) * 2007-09-17 2009-03-26 Kosta Steliou Mitochondria-targeting antioxidant therapeutics
EP2433133A2 (en) * 2009-05-20 2012-03-28 Universite De Geneve Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
ES2869423T3 (es) 2011-08-08 2021-10-25 Immunomet Therapeutics Inc Derivados de fenilbiguanida N1-amina cíclica-N5-sustituidos y composición farmacéutica que comprende los mismos
RU2522557C1 (ru) * 2013-04-09 2014-07-20 государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СибГМУ Минздрава России) СПОСОБ ПОЛУЧЕНИЯ п-ИОДФЕНИЛЖИРНЫХ КИСЛОТ
US9896466B2 (en) 2013-04-24 2018-02-20 Kkcg Ag Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
JP2016523926A (ja) 2013-07-01 2016-08-12 ユニバーシティ オブ ジョージア リサーチ ファンデーション，インコーポレーテッド 抗癌療法のための細胞ミトコンドリアへの治療剤の正確な送達
WO2015156943A1 (en) * 2014-03-10 2015-10-15 Aravind Musuluri Augmenting search results
CN107137390A (zh) * 2017-06-09 2017-09-08 中国人民解放军第三军医大学第附属医院 氯化二亚苯基碘鎓在制备治疗细菌感染药物中的用途

Also Published As

Publication number Publication date
PH12020550476A1 (en) 2021-03-15
IL274116A (en) 2020-06-30
CA3079952A1 (en) 2019-05-02
JP2021500374A (ja) 2021-01-07
WO2019083997A1 (en) 2019-05-02
SG11202003675PA (en) 2020-05-28
US20200246344A1 (en) 2020-08-06
US11497749B2 (en) 2022-11-15
EP3700512A4 (en) 2021-08-11
CL2020001108A1 (es) 2020-10-23
BR112020008022A2 (pt) 2020-10-27
EP3700512A1 (en) 2020-09-02
CN111565715A (zh) 2020-08-21
ECSP20027220A (es) 2020-06-30
MX2020004211A (es) 2020-08-13
CU20200039A7 (es) 2021-03-11
KR20200069365A (ko) 2020-06-16
ZA202002663B (en) 2022-06-29
PE20210166A1 (es) 2021-01-28
AU2018354143A1 (en) 2020-05-14
RU2020116649A (ru) 2021-11-30

Similar Documents

Publication Publication Date Title
PH12020550476A1 (en) Mitoflavoscins: targeting flavin-containing enzymes eliminates cancer stem cells (cscs) by inhibiting mitochondrial respiration
PH12019501557A1 (en) Bacillus isolates and uses thereof
AU2019264537A1 (en) Beta-lactamase inhibitors
MY197635A (en) Benzooxazole derivatives as immunomodulators
MX2020006490A (es) Compuestos macrociclicos para tratar enfermedades.
PH12019502056A1 (en) Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
PH12015501953A1 (en) Substituted nucleotide analogs
EP4036240A3 (en) Transduction buffer
WO2013122888A3 (en) Methods of treating bacterial infections
MX2015007556A (es) Derivados de manosa para tratar infecciones bacterianas.
WO2012106735A3 (en) Plasma-assisted skin treatment
MY182891A (en) Novel quinoline-substituted compound
UA104885C2 (uk) Ізотіазолілоксифеніламідини та їх застосування як фунгіцидів
WO2013112699A3 (en) Proteasome activity enhancing compounds
PH12019502892A1 (en) Mitoketoscins: mitochondrial-based therapeutics targeting ketone metabolism in cancer cells
WO2013112651A3 (en) Proteasome activity modulating compounds
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MY200161A (en) Bacteria for targeting tumors and treating cancer
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer
IN2013MU03216A (es)
NZ610547A (en) Novel monensin derivatives for the treatment and prevention of protozoal infections
WO2020104649A3 (en) Novel rna compositions and methods for inhibiting angptl8
MX2020005424A (es) Composiciones y metodos para terapia contra el cancer.
MX2013012603A (es) Vancomicina liposomal para el tratamiento de infecciones por estafilococo aureus resistente a la meticilina (sarm).